NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02595073,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT02595073,,COMPLETED,"Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis",YES,Atopic Dermatitis,DRUG: DSXS|DRUG: Placebo,"The Number of Patients in Each Treatment Group That Have Clinical Success, Clinical Success defined using the following scores at Visit 4 (Day 28 ± 2): At least a 2-grade improvement from the baseline IGA score (i.e., clear \[0\] or almost clear \[1\]) AND A score of clear or mild (0 or 1) for both erythema and induration/papulation/edema, 28 days","Change From Baseline in %BSA Affected at Day 28 ± 2, The change in %BSA Affected from Visit 1 Baseline (Day 1) to Visit 4 End of Treatment (Day 28 ± 2), 28 days",,Taro Pharmaceuticals USA,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,124,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",DSXS 1504,2015-09-04,2017-01-17,2017-08-29,2015-11-03,2018-11-12,2018-12-07,"Taro Pharmaceuticals USA Inc., Hawthorne, New York, 10532, United States",
